Morning Buzz: Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), Nanosphere, Inc. (NASDAQ:NSPH), Aerohive Networks, Inc. (NYSE:HIVE), NRG Yield, Inc. (NYSE:NYLD),

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) remains on schedule with its two Phase III trials for SPN-810 and the Phase IIb trial for SPN-812. During the first quarter, we are actively recruiting and screening patients for all trials. Phase III data for SPN-810 is expected to be available by mid 2017, and data from the SPN-812 Phase IIb trial is expected to be available by early 2017.

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) belongs to Healthcare sector. Its net profit margin is 8.70% and weekly performance is 6.07%. On last trading day company shares ended up at $13.99. Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) distance from 50-day simple moving average (SMA50) is 0.45%.

Nanosphere, Inc. (NASDAQ:NSPH) announced publication of a study that demonstrates the clinical and economic impact of implementing rapid sepsis diagnostic testing with the Company’s FDA-cleared Verigene® Gram-Positive Blood Culture Test (BC-GP) in a pediatric patient population.

Nanosphere, Inc. (NASDAQ:NSPH) shares increased 19.32% in last trading session and ended the day at $0.87. NSPH Gross Margin is 41.20% and its return on assets is -107.50%. Nanosphere, Inc. (NASDAQ:NSPH) quarterly performance is -24.91%.

On 25 February, Aerohive Networks, Inc. (NYSE:HIVE) announced that CRN®, a brand of The Channel Company, has named Michael O’Brien, vice president of global channels to its prestigious list of 2016 Channel Chiefs.

On 03 March, Aerohive Networks, Inc. (NYSE:HIVE) shares decreased -1.97% and was closed at $4.98. HIVE EPS growth in last 5 year was -29.40%. Aerohive Networks, Inc. (NYSE:HIVE) year to date (YTD) performance is -2.54%.

On 26 February, NRG Yield, Inc. (NYSE:NYLD) reported fourth quarter 2015 financial results including Adjusted EBITDA of $183 million and CAFD of $15 million, which resulted in full year Adjusted EBITDA and CAFD for 2015 of $720 million and $179 million, respectively. Net income attributable to Class A and Class C stockholders for the twelve months ended December 31, 2015 was $33 million or $0.40 per Class A and Class C common share.

NRG Yield, Inc. (NYSE:NYLD) ended the last trading day at $13.72. Company weekly volatility is calculated as 5.64%. NRG Yield, Inc. (NYSE:NYLD) showed a weekly performance of 8.59%.

Northeast Investment Management raised its position in shares of Novo Nordisk A/S (NYSE:NVO) by 1.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission.

Novo Nordisk A/S (NYSE:NVO) shares decreased -1.44% in last trading session and ended the day at $52.60. NVO Gross Margin is 85.00% and its return on assets is 41.50%. Novo Nordisk A/S (NYSE:NVO) quarterly performance is -6.39%.

Leave a Reply

Your email address will not be published. Required fields are marked *